335 related articles for article (PubMed ID: 18829696)
1. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
[TBL] [Abstract][Full Text] [Related]
2. Microglial activation in presymptomatic Huntington's disease gene carriers.
Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599
[TBL] [Abstract][Full Text] [Related]
3. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
[TBL] [Abstract][Full Text] [Related]
4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
5. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
6. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
[TBL] [Abstract][Full Text] [Related]
7. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.
Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ
Exp Neurol; 2008 Nov; 214(1):112-6. PubMed ID: 18723016
[TBL] [Abstract][Full Text] [Related]
8. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.
Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P
Neurobiol Dis; 2010 Feb; 37(2):356-61. PubMed ID: 19853661
[TBL] [Abstract][Full Text] [Related]
9. Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P
Neurology; 2006 Jun; 66(11):1638-43. PubMed ID: 16769933
[TBL] [Abstract][Full Text] [Related]
10. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
[TBL] [Abstract][Full Text] [Related]
11. Imaging microglial activation in Huntington's disease.
Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
Brain Res Bull; 2007 Apr; 72(2-3):148-51. PubMed ID: 17352938
[TBL] [Abstract][Full Text] [Related]
12. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
[TBL] [Abstract][Full Text] [Related]
13. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
[TBL] [Abstract][Full Text] [Related]
14. Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models.
van Wamelen DJ; Aziz NA; Roos RA; Swaab DF
J Neuroendocrinol; 2014 Nov; 26(11):761-75. PubMed ID: 25074766
[TBL] [Abstract][Full Text] [Related]
15. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
[TBL] [Abstract][Full Text] [Related]
16. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
[TBL] [Abstract][Full Text] [Related]
17. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary rehabilitation reduces hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study.
Bartlett DM; Dominguez D JF; Lazar AS; Kordsachia CC; Rankin TJ; Lo J; Govus AD; Power BD; Lampit A; Eastwood PR; Ziman MR; Cruickshank TM
J Neurol Sci; 2020 Jan; 408():116522. PubMed ID: 31665619
[TBL] [Abstract][Full Text] [Related]
19. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
Antonini A; Leenders KL; Eidelberg D
Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
[TBL] [Abstract][Full Text] [Related]
20. Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease.
Bellosta Diago E; Pérez Pérez J; Santos Lasaosa S; Viloria Alebesque A; Martínez Horta S; Kulisevsky J; López Del Val J
Parkinsonism Relat Disord; 2017 Nov; 44():95-100. PubMed ID: 28935191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
